PMID- 34506831
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20211230
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
VI  - 164
DP  - 2021 Nov
TI  - Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced 
      melanoma.
PG  - 1-5
LID - S0167-8140(21)06715-3 [pii]
LID - 10.1016/j.radonc.2021.08.021 [doi]
AB  - We analyzed CTCAE adverse events of sequential Carbon Ion radiotherapy (CIRT) and 
      immune checkpoint inhibitors (ICIs) in advanced melanoma patients. The 
      frequencies of early and late adverse events (AEs) were 100% and 82% of patients, 
      respectively. The frequency of G3+ AEs was in line with the literature.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Cavalieri, Stefano
AU  - Cavalieri S
AD  - Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei 
      Tumori, Milan, Italy.
FAU - Ronchi, Sara
AU  - Ronchi S
AD  - Radiation Oncology Clinical Department, National Center for Oncological 
      Hadrontherapy (CNAO), Pavia, Italy. Electronic address: sara.ronchi@cnao.it.
FAU - Barcellini, Amelia
AU  - Barcellini A
AD  - Radiation Oncology Clinical Department, National Center for Oncological 
      Hadrontherapy (CNAO), Pavia, Italy.
FAU - Bonora, Maria
AU  - Bonora M
AD  - Radiation Oncology Clinical Department, National Center for Oncological 
      Hadrontherapy (CNAO), Pavia, Italy.
FAU - Vischioni, Barbara
AU  - Vischioni B
AD  - Radiation Oncology Clinical Department, National Center for Oncological 
      Hadrontherapy (CNAO), Pavia, Italy.
FAU - Vitolo, Viviana
AU  - Vitolo V
AD  - Radiation Oncology Clinical Department, National Center for Oncological 
      Hadrontherapy (CNAO), Pavia, Italy.
FAU - Villa, Riccardo
AU  - Villa R
AD  - Radiation Oncology Clinical Department, National Center for Oncological 
      Hadrontherapy (CNAO), Pavia, Italy.
FAU - Del Vecchio, Michele
AU  - Del Vecchio M
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy.
FAU - Licitra, Lisa
AU  - Licitra L
AD  - Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei 
      Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of 
      Milan, Italy.
FAU - Orlandi, Ester
AU  - Orlandi E
AD  - Radiation Oncology Clinical Department, National Center for Oncological 
      Hadrontherapy (CNAO), Pavia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210908
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - *Heavy Ion Radiotherapy/adverse effects
MH  - Humans
MH  - Immune Checkpoint Inhibitors
MH  - *Melanoma/drug therapy
OTO - NOTNLM
OT  - Adverse events
OT  - Carbon ion radiotherapy
OT  - Carbon ion radiotherapy and immunotherapy combination
OT  - Immune checkpoint inhibitors
OT  - Mucosal melanoma
COIS- Conflict of interest statement Stefano Cavalieri, Sara Ronchi, Amelia Barcellini, 
      Maria Bonora, Barbara Vischioni, Viviana Vitolo, Riccardo Villa and Ester Orlandi 
      declare no conflict of interest. Michele Del Vecchio has served as an advisor and 
      consultant for Novartis, BMS, MSD, Pierre Fabre and Sanofi. Lisa Licitra has 
      received funding (for her Institution) for clinical studies and research outside 
      the submitted work from AstraZeneca, Boehringer Ingelheim, Eisai, Merck Serono, 
      MSD, Novartis, and Roche; has received compensation for service as a 
      consultant/advisor and/or for lectures from AstraZeneca, Bayer, Bristol-Myers 
      Squibb, Boehringer Ingelheim, Debiopharm, Eisai, Merck Serono, MSD, Novartis, 
      Roche, and Sobi; she has received travel coverage for medical meetings from 
      Bayer, Bristol-Myers Squibb, Debiopharm, Merck Serono, MSD, and Sobi.
EDAT- 2021/09/11 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/09/10 20:12
PHST- 2021/06/22 00:00 [received]
PHST- 2021/08/13 00:00 [revised]
PHST- 2021/08/28 00:00 [accepted]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
PHST- 2021/09/10 20:12 [entrez]
AID - S0167-8140(21)06715-3 [pii]
AID - 10.1016/j.radonc.2021.08.021 [doi]
PST - ppublish
SO  - Radiother Oncol. 2021 Nov;164:1-5. doi: 10.1016/j.radonc.2021.08.021. Epub 2021 
      Sep 8.